Reported Saturday, Jazz Pharmaceuticals Showcased Updated Survival Data From The HERIZON-BTC-01 Trial Of Zanidatamab In HER2-Positive Biliary Tract Cancer At ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals presented updated survival data from the HERIZON-BTC-01 trial of Zanidatamab in HER2-Positive Biliary Tract Cancer at ASCO 2024. The trial showed a median overall survival of 15.5 months for patients with IHC 2+ or 3+ and 18.1 months for patients with IHC 3+ tumors. The median duration of response increased to 14.9 months with approximately two years of follow-up.
June 03, 2024 | 8:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals presented promising updated survival data for Zanidatamab in HER2-Positive Biliary Tract Cancer at ASCO 2024. The data showed improved median overall survival and duration of response, which could positively impact the company's stock price.
The updated survival data for Zanidatamab presented at a major conference (ASCO 2024) is likely to be viewed positively by investors. Improved median overall survival and duration of response are significant indicators of the drug's efficacy, which could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100